Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

2(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

8(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(5)

Other(1)

Detailed Status

Completed5

Recruiting2

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 28 (100.0%)

Trials by Status

suspended113%

completed563%

recruiting225%

Recent Activity

2 active trials

Showing 5 of 8

suspendedphase_2

Clinical Trials (8)

Showing 8 of 8 trials

NCT05006781Phase 2

The Dose Finding Study of DAOIB Added to tDCS for AD

Suspended

NCT05764538Phase 2

DAOIB for the Treatment of Brain Fog

Recruiting

NCT05582161Phase 2

Efficacy Biomarkers of DAOIB for Dementia

Recruiting

NCT04736355Phase 2

DAOIB for the Treatment of Mild Cognitive Impairment

Completed

NCT04737096Phase 2

DAOIB Combined With tDCS for Early-phase Dementia

Completed

NCT02239003Phase 2

NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment

Completed

NCT02103673Phase 2

DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia

Completed

NCT01600469Phase 2

NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8